On February 5, 2026, President Trump released another namesake initiative, this time aimed at prescription drug prices. The new program, TrumpRx, is advertised as delivering “the world’s lowest prices ...

To combat rising costs, BCBSM installed a multi-year cost-cutting initiative to slice $600 million off its total spend, which has resulted in hundreds of job losses at the insurer. A total of 1,300 ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its ...

The Internet is a global network of networks. The Internet is a global network of networks. When the Internet is functioning as intended, any user can access any part of it, no matter where they are ...

Forbes contributors publish independent expert analyses and insights. Dr. Tracy Brower writes about joy, community and the future of work. This voice experience is generated by AI. Learn more. This ...

The best VPNs can make your online life more private with software that's convenient and cheap — sometimes even free. While keeping your IP address invisible, you can use your VPN to explore streaming ...

MiraLAX is an over-the-counter drug that works to treat constipation by drawing water into your colon, softening your stool and making it easier to pass. Your response to this drug may vary based on ...

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates. Patients with ankylosing spondylitis ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

According to a latest report by Coherent Market Insights, the global Humira Market is projected to be valued at USD 4.68 Bn in 2025, but is expected to decline to USD 1.20 Bn by 2032, experiencing a ...

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story. The ...